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ABSTRACT
For the past several decades, global health research and policy have raised
the alarm about the growing threat of counterfeit and low-quality drugs
(henceforth ‘fakes’). These high-profile and regularly-repeated claims
about ‘fake drugs’ pepper scholarly publications, grey literature, and
popular writing. We reviewed much of this work and found that it
shares two characteristics that sit awkwardly alongside one another.
First, it asserts that fake drugs constitute an urgent threat to lives.
Second, it reports trouble with ‘gaps’ in the evidence on which their
claims are based; that data is weaker and less conclusive than
anticipated. Given the ubiquity of and urgency with these claims are
made, we found this juxtaposition perplexing. To understand this
juxtaposition better, we undertook a close reading of the strategies
authors employed to negotiate and overcome data and evidence ‘gaps’
and asked questions about the cultures of scholarly publishing in global
health research. We argue that a scholarly commitment to studying
fakes despite--rather than because of—the evidence functions to
support the continuation of similar research. It also works against asking
different questions—for instance regarding the lack of easy access to
pharmacological data that might make it possible to know fakes
differently.
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Introduction
In March 2012, The Lancet ran the editorial ‘Counterfeit drugs: A growing global threat’ (Lancet
2012). The piece recounted recent seizures of bad drugs in the US, and went on to warn that,
although concerns about drug safety previously focused on Africa and Asia, the globe’s entire
drug supply chain was now under threat. The concerns raised in the article are not new. Over the
last few decades, research and policy have raised the alarm about the danger that fake pharmaceu-
ticals pose to global health.
This narrative – that fake drugs threaten health – has been repeated so often and with such cer-
tainty that it has come to seem common-sensical. To explore the evidentiary basis of these concerns,
we subjected these high-profile and oft-repeated claims in this body of published work to close scru-
tiny, following the paper trail of citation: sources, data, and experts. The upshot: Our reading of the
published evidence points to a more complicated picture.
This scholarship maintains that fake drugs constitute an urgent problem for global health because
fake drugs constitute an immediate threat to lives (e.g. Glass, 2014; Harris et al., 2009; Khan & Khar,
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2015; Mackey et al., 2011, 2015). Such assertions are often treated as self-evident. For example, one
frequently repeated claim is that India produces a staggering 75% of the world’s counterfeit drugs, yet
this piece of information is not attributed to any source (e.g. Khan & Khar, 2015, p. 2; Verma et al.,
2014, p. 141). At the same time, the same papers report surprise at how little convincing evidence
they found to support their claims about the urgent dangers presented by fake drugs (see also Rah-
man et al., 2018). This situation is not unique to the problem of fakes and we suspect that a similar
reading of the published literature of other public health issues would result in similar findings. Our
purpose is not to deconstruct how claims are made but rather investigate the ways in which fake
drugs have become a widely accepted concern in global public health research. In particular, we
are responding to calls to inform the development of new methodologies and approaches to fakes
and suggest that better understanding cultures of knowledge production are key to this learning
process.
This paper has three parts. First, we report on our initial findings from reviewing the literature.
We recount the substantial mismatch between (a) the strength of claims about the prevalence and
dangers of fake drugs, and (b) the recognition that fakes are difficult to measure, evidence and con-
ceptualise. Second, we consider the rhetorical strategies that papers employed to negotiate and over-
come problems with the evidence in order to make claims about the extent of the problem of fakes.
Third, we explore the implications of this mismatch for the politics of knowledge, asking: What
might these ‘evidence gaps’ tell us about the cultures of knowledge in the production, circulation,
and consumption of scholarly literature itself? In particular, we note that responses to the challenges
of generating data and evidence of fakes has been two-fold. We highlight a series of ‘workarounds’
used by scholars in their research and the reporting of fakes – that is, methods for circumventing
problems with available data and evidence. From there, we show how these workarounds emerge
in lieu of asking corollary questions about access to data on pharmaceuticals’ quality, such as
those held by states or manufacturers.
Our approach focuses attention on the politics of knowledge. That is, rather than taking a pro-
blem – such as fake drugs – as self-evident, we join others from history, sociology, anthropology,
and science and technology studies who investigate the conditions that allow a phenomenon to
become an object of concern (e.g. Latour, 1987; Reinarman, 1988; Rekdal, 2014). In so doing, we
ask: what can we discern about the cultures of knowledge at play in the scholarship on fake
drugs? We argue that the upshot of the persistent mismatch between bold claims and weak evidence
is to frame fake drugs as an unknowable problem. Rendering fake drugs as unknowable matters, we
argue, because it misdirects (Peeters Grietens et al., 2019) attention away from the conditions that
produce drugs’ unknowability – that is, the structural conditions that shape what we know and
the ‘closed shop’ that is the pharmaceutical industry’s approach to their own data (Sismondo, 2018).
Global public health scholarship on pharmaceuticals has attended to the problem of fake drugs for
the past few decades. Alongside this, intellectual property legal thinkers, such as those associated
with Third World Network, have produced large numbers of pamphlets, books, memos and online
resources as part of campaigns that criticised anti-counterfeit policing of pharmaceuticals as this
policing emerged as part of international trade regulations at the close of the twentieth and into
the twenty-first centuries (https://www.twn.my/publications_ipr.htm). Nevertheless, this substantial
attention to fake drugs has focused our collective critical gaze almost exclusively onto the operations
of formal regulatory regimes. Our approach departs from these concerns.
Instead of exploring the efficacy or politics of formal regulatory regimes, in this article we take
inspiration from recent scholarship in critical global health. This new body of work asks if it is in
fact possible to distinguish clearly between the ‘real’ and the ‘fake’ even though these categories
structure so much of the design, delivery, and experience of global health (Kingori & Gerrets,
2019; see also all of the accompanying articles in their guest-edited special issue). We also locate
our intervention within the lively scholarly subfield of the anthropology and history of pharmaceu-
ticals, where scholarship are asking vital questions about the production, circulation, and consump-
tion of pharmaceuticals (Dumit, 2012; Greene, 2014; Hardon & Sanabria, 2017; Hayden, 2007,
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2010, 2013; Kamat & Nichter, 1997, 1998; Nichter & Vuckovic, 1994; Peterson, 2014; Petryna et al.,
2006; Sarojini et al., 2010; Sunder Rajan, 2017; van der Geest, 1982; van der Geest et al., 1996). This
scholarship tracks the social lives of pharmaceuticals. It tells stories of their potential and of broken
promises. It powerfully illuminates the uneven global distribution of pharmaceuticals’ therapeutic
benefits.
Within broader medical humanities enquiry, questions of what is at stake in claims of pharma-
ceuticals’ fakeness, however, have only just begun to attract substantial attention (Cloatre, 2016; Gry-
seels et al., 2019; Hodges, 2019; Hornberger, 2018, 2019; Meek, 2018; Quet, 2018). Julia Hornberger’s
ethnographic analyses of the material and discursive careers of fake drugs is particularly important
(2018, 2019). Hornberger explores how everyday practices of anti-counterfeit policing are rooted in
the belief that large criminal conspiracies are to blame for the circulation of bad pharmaceuticals. She
shows how this belief has, in turn, fuelled extensive funding for anti-counterfeit policing and pro-
ducts, such as the holograms or the barcodes that are now included as part of pharmaceutical pro-
ducts’ packaging. In particular, Hornberger’s work shows how as the markets for – and the
profitability of – anti-counterfeit policing products have grown, their chief observable effect has
not been to make the global drugs supply chain safer, but instead to promote ever more wide-spread
suspicions about the safety of all pharmaceuticals. By exploring the distribution of suspicion, Horn-
berger has opened up scholarly inquiries of fakeness as part and parcel of pharmaceuticals’ social
lives.1
Methodology: Conceptual tools and practical tactics
We write from our positions in the humanities and qualitative social sciences. We are invested not
only in the epidemiological outcomes of global health practices, but also in the epistemological poli-
tics of global health knowledge. In order to explore the politics of knowledge, in this paper we under-
stand global public health research on fake drugs as not simply reporting knowledge but also
constituting it (Cohn, 1996; Hull, 2012; Sismondo, 2018). Our paper seeks to answer the questions:
What is the underlying logic that makes these scholarly claims make sense? How do they, in fact,
perform a particular reality? To ask questions of the culture of knowledge allows us to take a step
back from the purported self-evident nature of the problem of fake drugs.
We focus in particular on the cultures of knowledge that shape how evidence is generated and
framed in order to make claims about fakes. This involved analysing the discursive mechanisms
by which uneven or ambiguous data and evidence about fake drugs is converted into global health
claims. We trace how the material discursive work of scholarly practice constitute wider rhetorical
patterns and are part of a rich discursive ecology that structures research of the contemporary global
circulation of pharmaceuticals. To do this, our approach draws on two sets of scholarly traditions,
and performs methods that in many ways mimic much of the research we analyse: the ‘desk review’.
Based on a review of published findings we apply the methodological tools of ‘close reading’ and
‘reading against the grain’ that characterise much research on what has come to be seen as the ‘poli-
tics of knowledge’ across our respective disciplines: sociology and anthropology (author 2) and cul-
tural history (author 1) (e.g. Bell, 2015; Cohn, 1996; Mkhwanazi, 2016). This methodology is
particularly good at surfacing both the explicit and implicit assumptions that frame scholarly prac-
tice and its outputs. Focusing on rhetorical strategies of argumentation in scientific papers (Latour,
1987) is an opportunity to illuminate the broader culture of knowledge that this body of scholarship
both draws on and reproduces.
The paper takes inspiration from those who have begun to explore the scholarly preoccupation
with fakeness to discern the story it tells us about the production, circulation, and consumption
of scholarly research itself. Whereas Dumit (2012) uses a methodology of close reading of claims
about pharmaceutical advertisements, in this article, we identify patterns of argumentation within
scholarly writing about fake pharma and read these patterns ‘against the grain’. In short, by
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employing this methodology we bring one set of conceptual framings to bear upon a body of scho-
larly research that explicitly pursues different ends.
We sought to take a snapshot of the literature, which means our sample is necessarily indicative
rather than comprehensive (see Appendix for a full list of sources consulted in the review). Unlike
the ‘systematic review’ that seeks to represent the literature that has been published, our aim is to
demonstrate how the careers of certain problems have been sustained. The analysis we present
also anticipates the modes by which cultures of scholarly publishing will continue to participate
in its construction, and what as a result it might foreclose in terms of understanding and interrogat-
ing the social and political conditions of fakes.
By performing the methods of the studies we reviewed and analysed, we could understand how
the problem of fakes is constructed and circulated through data practices, for instance, by sampling
techniques, through tracing relationships between data sets, and by paying attention to citations and
references in publications. Indeed, because many of the articles we studied explicitly discussed their
search terms and search engines, we ran the same search terms (e.g. ‘fake’, ‘counterfeit’, ‘substan-
dard’, ‘spurious’, ‘falsified’, and so on) through the same search engines (e.g. PubMed, Google Scho-
lar, etc.) to create our sample: 42 scholarly articles all identified over several months in late 2017 and
early 2018. Additionally, we augmented our initial results by soliciting suggestions from our informal
scholarly networks. Finally, we ‘followed the paper trail’; we took an initial sample and read all of the
pieces carefully for the terms contained in their references and bibliographies. We then added these
to our sample as well (see Appendix for a full list of all literature collected and consulted).
Analysis involved identifying patterns in the rhetorical and material strategies by which ‘evidence
gaps’ were worked around in the selected articles for review. This was followed by a close reading of
examples of rhetorical strategies together and comparatively, in order to examine the politics of
knowledge at play in these. We then considered what narratives about fakes were performed through
the interpretive work of negotiating and overcoming ‘evidence gaps’: What understandings of fakes
did they open up? Which did they foreclose?
Findings: How the published literature negotiate and manage evidence gaps
Broadly, we found that all publications claimed fake drugs were a prevalent and growing problem for
global health. Such claims were often followed by corollary assertions about the urgent dangers to
health fakes pose. However, when we subjected the claims made in scientific publications to closer
scrutiny we found persistent ‘evidence gaps’, which were also acknowledged in the published litera-
ture. Our identification of these ‘gaps’ matter because, in our analysis they function as empirical
examples of the ways in which research and findings on fakes are produced, circulate and gain trac-
tion. Philosopher, sociologist and anthropologist Bruno Latour argues that a key rhetorical strategy
in science is ‘bringing others in’ through citation practices that can help build an ‘argument from
authority’ (1987, p. 31). In what follows, the discursive strategies of scholarly publishing are not con-
sidered solely in terms of how accurately they represent ‘the problem of fake drugs’ but in terms of
the relations that materialise and mobilise the problem of fakes as a global health concern. For
instance, the literature has many potential effects in terms of future research, the distribution of
resources and funds, and regulations and legislation, among others. Although our focus is primarily
on peer-reviewed scholarship, we found similar rhetorical strategies in grey literature. In what fol-
lows we describe four rhetorical patterns to overcome and make sense of ‘evidence gaps’ in research,
and point to the implications of these practices and strategies on how the problem of fakes has
become a concern and priority for global health.
Reporting ‘evidence gaps’
The following is typical in an opening or conclusion of a scientific article on fakes, wherein the paper
emphasises the absence of data on fake drugs: ‘Unfortunately, reliable information on the true public
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health and socioeconomic impacts of substandard and falsified medical products is sparse’ (WHO,
2017a, p. 1). In an even more detailed way, one report details how the extent of ‘data gaps’means the
generation of credible statements about fakes subsequently limited:
The original intention was to develop a simple model to allow for ‘guesstimated’ quantification of the extent of
the contribution made to the development of antimicrobial resistance by poor quality medicines. However, the
data gaps are too extensive to allow for any credible estimates to be developed. (Pisani, 2015, p. 4)
This declaration struck us as particularly significant when it was made in articles that were reviews of
published scholarship (like our own). For example, there are published articles on the scale and
nature of the problem of fake drugs through conducting search-based literature reviews using
PubMed (Koczwara & Dressman, 2017; Rahman et al., 2018). In these specific cases, it was concluded
that it was not possible to make a reliable statement about the prevalence of counterfeit drugs. Kocz-
wara and Dressman point to the ‘heterogeneity of the results’ (2017, p. 2921) – a euphemism for what
we refer to as ‘evidence gaps’. In another paper, it is stated that: ‘many of the reports identified in our
study only provided seriously inadequate or even conflicting data’ (Rahman et al., 2018, p. 1300).
Evidence gaps were identified in scientific publications, but they were also materialised by report-
ing on conditions that might ‘host’ the missing evidence. Whilst signalling the urgency of the pro-
blem of fakes, in terms of the threat fakes pose to life-threatening conditions that can only be treated
with life-saving medicines, for instance, many papers drew on documented cases of ill health caused
by bad drugs that were not life-saving drugs. Instead they were products such as skin lighteners (see
Hornberger, 2018 for a discussion of this). In other papers, fakes of both medical and non-medical
products were presented and their problem defined in terms of their availability on the market. For
example, one paper paints a picture of how fakes – both medicines and non-medical products – were
presented to inquisitive passers-by and presumably potential consumers:
Such exposure presents a major health challenge as the market is likely to be proliferated with SF [substandard
& falsified] pharmaceutical products for major diseases such as antiretroviral therapy (ART) anti-tuberculosis
(anti-TB), anti-malarial therapy and other essential medicines. (Gwatidzo et al., 2017, p. 82)
Here, the possibilities of the market extend claims about fakes’ threat to health by using the extent of
their reach (Hornberger, 2018) as indicative of ‘evidence gaps’. Similar claims were made about the
absence of regulation in online markets (Interpol, 2014; see also discussion by Clark, 2015). Trouble
controlling the global drug market has been used as a signal for the possible extent and availability of
fakes to innocent consumers.
Supplementing evidence
Although we were surprised at the ubiquitous acknowledgment of ‘evidence gaps’ in scientific pub-
lications, we found these statements did not always lead to a corollary questioning or moderation of
claims about the prevalence of fake drugs. Instead, we observed a series of material and discursive
ways of accounting for the ambiguity, uncertainty, and inaccessibility of data. Four ways in which
the published literature used data to supplement the heterogeneous evidence base were identified:
(a) refashioning multiple data; (b) sourcing data beyond biomedical research; (c) circumventing
absent data with small samples and the ‘extreme case;’ and by (d) connecting fakes to other contem-
porary global health challenges, specifically anti-microbial resistance, for which there is data and evi-
dence to build on.
Refashioning multiple data
Our analysis highlighted how the absence of data and evidence for a causal relation between fakes
and health led to the pooling of different forms of data, gathered from a variety of sources and
through a range of methods (e.g. Almuzaini et al., 2013; Khan & Khar, 2015; Koczwara & Dressman,
2017; Medina et al., 2016; Wertheimer & Norris, 2009). Bringing together diverse forms of data to
make knowledge claims is not necessarily problematic, however the way in which they were put into
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dialogue created some comparisons that were insightful for understanding the cultures of knowledge
production. For instance, in some publications data practices included combining crime data, field
site sampling, mortality statistics, and results from lab studies to justify the extent of the problem of
fakes (Kaur et al., 2016; Mackey & Liang, 2011). Individually these distinct forms of evidence were
often shown to be limited in some way. Another example is a paper that detailed the development of
screening devices for testing the molecular composition of drug samples to create a gold-standard for
testing fakes (Kaur et al., 2016). This suggests that at the time of the research there were no effective
tools of measurement. Other articles indicated that characteristics of a product, like packaging, or the
conditions of places where medicines are sold, qualified something as fake, in lieu of evidence of the
absence of an active pharmaceutical ingredient (Bate et al., 2013; Fatokun, 2016; Shukla & Sangal,
2009). The process of pooling and collating different kinds of data – refashioning data – was there-
fore a key part of building claims about fakes, through new material discursive compositions of the
problem.
Sourcing data beyond scientific and biomedical literature
Secondly, demonstrating the presence of fakes involved the inclusion of undocumented sources, par-
ticularly with media reports and various journalistic accounts of fakes (e.g. Rahman et al., 2018; Ste-
vens & Haja Mydin, 2013). A survey of published literature notes that: ‘a significant part of the
published evidence regarding counterfeit antimicrobials derived from journalism rather than the
biomedical literature’ (Kelesidis & Falagas, 2015, p. 459). Some publications relied very heavily on
journalism to document fake drugs, for example, the study by the Interpol Pharmaceutical Crime
Directorate (2014). Following scholarly articles’ reference lists, we went on to read the journalism
cited but could not always find the data sources listed. This is not surprising or highly specific to
this field, but is rather indicative of a mechanism by which narratives about fakes continue to
grow and reproduce through academia (Rekdal, 2014).
Circumventing absent data: ‘Small’ data and the extreme case
The way in which fakes are reported in journalism, such as by developing narratives through
examples of specific instances of the fake drug industry’s existence or the harmful effects of fakes,
was in some ways reflected in how they were reported in scientific publications. We noted the fre-
quent use of what we call the ‘extreme case’ in our analysis. The extreme case is a version of small – or
inapposite or under-documented – data samples serving as evidence for claims about a larger pro-
blem. For example, in one article it was suggested that rather than extrapolation, presumably through
statistical methods, small and ‘unrepresentative’ data can offer insight into the problem of fakes:
… data analysis and samples collected by investigators in some of these studies were not necessarily represen-
tative of a large target area, and thus the prevalence obtained cannot be extrapolated to the whole country
studied. However, these studies give an insight into the problem and, following our assessment of methodology,
give the best evidence currently available in the literature. (Almuzaini et al., 2013, p. 6)
Small cases feed into a methodology of recirculating published literature that at once accepts the
absence of evidence while claiming the existence of the problem of fakes. Small cases become key
points in building a narrative understanding about the global circulation of fakes. For instance,
when fake cancer drugs are discovered, or reports of local outbreaks of disease due to available
drugs with no active pharmaceutical ingredient are found (Nayyar et al., 2015). ‘Small’ data is not
necessarily a problem, and indeed qualitative social science research often draws on situated case
studies to build empirical and theoretical claims. Yet rather than reflect on the problem-definition
or methodology of research into fakes, the small-case was often framed as evidence in the absence
of better evidence. Indeed, one major briefing report referred to a survey of medicines on sale at a
large bazaar in New Delhi which found that only 7.5% were genuine but where this percentage
came from was unclear (Stevens & Haja Mydin, 2013). The same report then cites a news article stat-
ing that twenty-two Indian pharmaceutical companies have been backlisted from exporting,
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importing and distributing drugs in Nigeria (Stevens & Haja Mydin, 2013, p. 5). Here, drugs from
India are linked to pandemics in Africa through data from highly situated and diverse data, and
despite an explicit discussion of the absence of precise data.
Connecting fakes to drug resistance
Another way in which ‘evidence gaps’ were worked around was by framing fake drugs as a possible
driver or intensifier of drug resistance. In our review, we found the logic that connects the relation-
ship between fakes and the existence of anti-microbial resistance to be deductive. That is to say, the
claim that fake drugs are readily available is used as a starting point for understanding the existence
of drug resistance (e.g. Bate et al., 2013; Newton et al., 2017).
The link between fake drugs and drug resistance was made by arguing that repetition of corre-
lation evidence of causal links: ‘Scientific theory and common sense thus both suggest an inevitable
link with [fake drugs and] antimicrobial resistance’ (Pisani, 2015, p. 12). Other articles discounted
evidence of efficacy when active pharmaceutical ingredient (API) doses were lower than expected,
claiming that the issue was not actually efficacy but long-term effects of drug resistance: ‘While
these drugs may work in some cases, the insufficient API dose may prevent patients’ chances of
cure and contribute to drug resistance’ (Bate et al., 2013, p. 3). With greater attention being paid
to the question of drug resistance (particularly in the case of life-saving drugs), our research suggests
that drug resistance enables the possibility of an effect of fake drugs to be evidenced empirically. For
instance, emerging research suggests that poor quality medicines, like fakes, might be contributing to
the development of drug-resistant pathogens in lower-income countries (Pisani, 2015, p. 39; see also
Pisani, 2016).
Similarly, presenting evidence of resistance in sites where there is a lack of regulatory infrastruc-
ture was another way to demonstrate the problem of fake drugs (e.g. Banerjee, 2015). As one group
writes: ‘[a]lthough a causal relation between poor quality artemisinin derivatives and artemisinin
resistance has not been confirmed, modelling analyses suggest that under-dosing patients can play
an important part in the spread of resistance’ (Nayyar et al., 2012, p. 488). By materialising data
about fakes through modelling, a narrative about fakes, low doses of antibiotics, and possible resist-
ance is subsequently mobilised. Introducing the concept of drug resistance was a way to infer under-
lying evidence exists. Speculative and theoretical work that sought to evidence a relationship between
fakes and AMR is a necessary part of scientific inquiry. We are not criticising this approach but
rather highlighting that what the ‘gap’ is in evidence is clearly unstable. Yet it is important to
note that one of the effects of this new line of inquiry is to deflect attention away from this unstable
evidence base.
Uncertain data as implicit evidence of hidden data
By detailing these four discursive strategies that sought to compensate for ‘evidence gaps’ we have
shown how they were used to demonstrate the existence of problem. Instead of treating ‘evidence
gaps’ as evidence of a lack of evidence, gaps themselves also became evidence of the need to generate
more evidence. This is particularly the case when concern that attention to the dangers of fakes may
diminish as a result of the absence of evidence was expressed. For instance, having explained that
data gaps were too extensive to allow for modelling, one paper argues that whilst ‘overall the picture
is one of great uncertainty… this is overwhelmingly more likely to be because of a lack of represen-
tative information than the lack of a significant problem’ (Pisani, 2015, p. 3). We characterise this
assertion as ‘uncertain data as implicit evidence of hidden data’ and point to the structural effects
that uncertainty plays in determining how scientific resources are distributed in order to fill ‘knowl-
edge gaps’. As Kelly et al. (2020) highlight, clinical and public health uncertainty define global health
problems in ways that reflect wider cultures and power dynamics.
In short, we suggest that despite uncertain data and evidence there is a collective refusal of the
possibility that fakes themselves might not exist, or at least not exist in the ways they are currently
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imagined. Further, ‘data gaps’ became evidence of the purposeful hiding of data. For example, some
authors suggested that weak or uncertain data was an effect of criminal elements outsmarting sur-
veillance mechanisms: ‘Despite clear global public health threats, surveillance for counterfeit medi-
cines remains extremely limited, with available data pointing to an increasing global criminal trade
that has yet to be addressed appropriately’ (Mackey & Liang, 2013, p. 233; also see Nayyar et al.,
2015). Similarly, in a different paper it is stated that: ‘Only few published data admit the extent of
the problem and its influence on public health. Thus, there is requirement of immediate attention
and research by the regulatory authority towards this public safety issue’ (Khan et al., 2015, p. 5).
We found that the published literature often asked open-ended questions, such as ‘How big is the
problem?’ as a way to indicate the scale of evidence their research has not yet been able to document
(Stevens & Haja Mydin, 2013, p. 2). In contrast, however, we found no one asking, ‘How small is the
problem?’
The trouble with categories
Finally, another way that the scientific publications we reviewed made sense of ‘evidence gaps’ was by
emphasising the problem of too many, or imprecise, definitions for fakes. As critical commentators
Cloatre (2016) and Quet (2018) note, the concept of fake or counterfeit medicines is strangely ill-
defined, even in formal settings. In the case of fake or counterfeit medicines, blurry legal definitions
construct corollary ontological instabilities. This is despite several decades’ worth of attempts by
organisations such as the World Health Organisation to produce meaningful categories, as Christo-
pher Sirrs’ meticulous archival research shows (2019). In other words, the problem of a lack of clear
definitions, alongside a proliferation of recognised categories of non-normative drug compounds, is
something all scholars face when generating and collating data on which to base their claims. How
scholars manage trouble with categories when researching fakes affects which world view and under-
standing of the issue is made visible (Bowker & Star, 1999).
To remedy the problem of too many, or ineffective, definitions, which makes evidential claims
about fakes difficult, many global public health articles offer new terminologies. Harris and col-
leagues (2009) write of this trouble and their decision to use the catch-all of ‘fakes’:
Counterfeit and substandard drugs are a serious and growing problem around the world – especially in less
developed countries. There are many reasons for this, including imitation, inappropriate packaging, poor man-
ufacturing processes, and improper conditions during transportation and storage. At the point of purchase,
such drugs share the common feature that they are not what they purport to be, so for simplicity we class
them all as ‘fakes’ in this paper. (p. 4)
Definitional troubles are a long-standing issue in the study of fakes. This is hardly an isolated
instance of struggling with the lived distance between distinct regulatory definitions (e.g. substan-
dard, unlicensed, counterfeit) and consumers’ understandings of the safety or efficacy of different
kinds of non-normative drugs, but rather indicates the ontological trouble of categorising fakes.
For instance, different places use different categories, and definitions are affected by highlighted
specific and situated circumstances:
International efforts to combat fake medicines have been hampered by the inability of countries to agree in a
legal definition of fake medicines. Legal scholars and health experts are now pushing for a global treaty to cor-
rect this problem and allow for greater cooperation between national authorities, but this will be many years off.
(Mydin and Stevens, 2013, p. 1)
Categories are also shaped by discipline and field of use. Experts in pharmacology or global public
health also encounter difficulties when using legal and regulatory categories in accordance with their
technical definitions. Another term used in the published literature is ‘counterfeit’ – itself an intel-
lectual property term – which refers to purposefully criminal activity and implies that drugs are
unsafe. For example, in describing an incident in India in which a vial of eye medication revealed
microbial contamination and no active ingredient a paper refers to the medication as ‘counterfeit’
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rather than ‘spurious’ (as per the Indian Legal Code) or ‘falsified’ (as per the WHO’s term) (Stewart
et al., 2016). Whilst the meaning of counterfeit may be popularly understood as both ‘criminal’ and
‘unsafe’, this is technically incorrect. To manufacture a counterfeit drug is certainly an illegal act, but
it is generally a civil offence: intellectual property theft. It is common knowledge among those fam-
iliar with pharmaceutical trade and policy a drug that is manufactured and distributed without hav-
ing first purchased (owning) the rights to do so could be identical to the ‘real’ thing in terms of its
therapeutic efficacy. The typical case of this is that of a generic drug.
Although legal definitions exist, how to make these function in practice is an ongoing challenge
and has led to the introduction of new terms and the removal of others (Sirrs, 2019). Disagreement
over definitions and the need to seek clarity regarding what kinds of fakes are of greater concern
usually result in requests for more ‘real data’ through improved surveillance, monitoring, and global
alert systems, something recently recognised by the WHO (2017b), which continues to seek to sim-
plify terminology. Nevertheless, for the purposes of this article, our point is that efforts to craft better
terminology still leaves under-investigated the basic question of the evidentiary basis of claims about
fake drugs. The problem of evidence cannot be addressed by better terminology alone (see Herrick,
2017).
Discussion: Constructing an unknowable problem?
Our research into the way claims about fake drugs are made and mobilised could, we suspect, be
applied to other public health issues with a similar result. However, what this paper emphasises is
the cumulative effect of a series of rhetorical practices in global health research of fakes through
the vehicle of the published article and other recognised forms of high-quality research (Latour,
1987). By locating the problem of fakes, as well as its possible solution, in data and evidence, together
the articles we review signal the possibility of knowing fakes. Yet, our analysis shows that, paradoxi-
cally, the ways in which fakes are currently being framed and talked about in science simultaneously
results in their unknowability.
Let us be clear: to call fake drugs an ‘unknowable problem’ is not to discount or dismiss the possi-
bility that consuming inefficacious drugs may cause substantial harm to health. But our review of the
literature tells us that – while papers regularly voice concern about the urgent problems that fake
drugs present – there is no consensus on what counts as an ‘evidence base’, neither in terms of
the scope nor the effects of fake drugs on global public health. In particular, we were struck by
the implicit assumption conveyed by much of the scholarship that there is no utility in questioning
the evidence gaps themselves.
For instance, published papers and policy reports always declared the importance of the problem
of fakes whilst acknowledging the lack of systematically collected data with sufficient sample sizes
and random sampling design (e.g. WHO, 2017). Our review showed that scientific publications
on fakes consistently chose not to question the conditions that produced such a paucity of data.
The same WHO (2017) report, for instance, proposes developing superior technical methods rather
than approaching research about fakes differently, despite other work in the field that has pointed to
the pharmaceutical industry severely constraining the circulation of data (e.g. Sismondo, 2018). Most
pharmaceutical data is produced, collected, and held by manufacturers – and classified as ‘proprie-
tary’ – yet this lack of access to data finds no place in the vast majority of global public health scholar-
ship about the problem of fake drugs (Sismondo, 2018). Data on drug quality is often held by
manufacturers and is unavailable for independent review by researchers. The availability of data
about drug quality is also hampered by the fact that, until very recently, independent testing of
drugs is typically prohibitively expensive for independent (that is, non-industry) researchers. In
other words, it is not just that people don’t use data, nor simply that data is absent. Rather, it appears
that data is, to a large degree, inaccessible to scholars.
Taken together, our findings point to an oversupply of curiosity about how fake drugs exist with-
out leaving clear evidence alongside a corollary undersupply of curiosity about how and why
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evidence gaps condition the possibility for knowledge about fake drugs. Our analysis shows that
this regular reiteration of urgency in the absence of good data has led to limited innovation in
research questions or designs.2 Instead, the cumulative effect is that scientific research is construct-
ing the ‘problem of fake drugs’ as knowable in a way that forecloses a discussion of the politics and
circulation of data and evidence. We argue that rather than being ‘unknown’, and therefore a pro-
blem that can be known (and resolved) through more research, taken together, one of the most
powerful effects of this body of scholarship has been the elision of other approaches and ways
of thinking about fakes.3
Conclusion: The ghost in the data
In closing, we would like to return to the title of this article. What is ‘ghost data’? By invoking the
term ‘ghost data’, we are conscious that we are using it slightly differently compared to how it func-
tions in other disciplines. Statisticians use the concept of ‘ghost data’ to refer to data that are not
actually there. As John Sall (quotes in Mejdal, 2017) explains, ‘Just as we appreciate the data we
have, we also need an appreciation of data that isn’t there. We need to know how to handle it,
know how to model with it, and put it to work’. Statisticians and others depend on the idea of
ghost data in order to model a fuller picture of non-existent and under-reported data, for example
in mortgage data:
Mortgage data for the years before the financial crisis of 2008 is a good example of informative missing [data].
When modelling the probability of a mortgage default, the results are biased if all the rows that have missing
values for variables like “income” and “debt-to-income ratio” have been dropped. Often the loan applicant
knew that providing those values would result in failure to qualify for the loan, so the values were omitted.
In the data table we supply with our sample data, the missingness of debt-to-income ratio is the most important
predictor of mortgage default. (Mejdal, 2017, p. X)
In other words, missing data itself can inform the picture, creating patterns that can produce new
knowledge. This is not a secret. In this sense, ghost data is very similar to the work that proxies
do in much epidemiological research. Indeed, mastering the art of quantitative analysis necessarily
demands that researchers acknowledge and determine the role played by ghost data.
In scholarly publishing on fake drugs, however, the role of ghost data is different. In much of the
scholarship we analysed, ghost data itself functions as justification for research. In other words, in the
production of knowledge about fake drugs within global public health, ghost data is a different kind
of problem and refers to the myth-like status of fake drugs within global public health. We wish to
reiterate that we do not claim that fake drugs do not exist, nor do we claim that the circulation of all
kinds of substandard or low-quality drugs does not exist. And especially, we do not claim that poor-
quality drugs cannot have a negative effect on health outcomes. But while there is broad agreement
that fake drugs may present a problem, there is little, if any, consensus regarding what kind of pro-
blem and for whom. Fake drugs are, at the very least, an awkward object of study: the scientific pub-
lications we reviewed imply that there are clear and knowable boundaries between ‘real’ and ‘fake’,
yet simultaneously demonstrate a conviction that the trade in fake drugs is nearly impossible to spot,
quantify, or prevent. Still, research continues to make new data and claims about fakes as a signifi-
cant global health problem.
In this paper, we have conducted an epistemic audit of what is gained and what is lost in the cur-
rent state of play of global public health knowledge about fake drugs. We have considered what the
larger epistemic effects of these persistent evidence gaps might be and concluded that these evidence
gaps actually function as a ghost in the data that might be misdirecting attention (Peeters Grietens
et al., 2019). This matters because by generating more data and highlighting absences we are hin-
dered from understanding the power dynamics that condition how we know fakes, such as how qual-
ity assurance data (or, indeed its absence) structures the contemporary political economy of
pharmaceuticals within global health.
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Were we writing a different paper – one which charted the rise in attention to worries about fake
drugs alongside the politics of the global trade in pharmaceuticals, we surely would have discussed
the ways in which attempts to regulate this trade have played out over the course of the last few dec-
ades. In particular, we would have paid attention to the 1995 agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS), as well as the respective careers of the World Trade Organiz-
ation (WTO) and the United States’ Food and Drug Administration (USFDA). Such an account
would also have considered the various legal battles that were waged over the regulation of inter-
national trade in pharmaceuticals in the face of the growth of India’s export commerce in low-
cost generic exports during this period, particularly in the wake of the AIDS crisis in Africa. And,
were we writing that other article we would certainly have attempted to account for the rise of
fake-talk in global public health scholarship on pharmaceuticals as part and part of this other history
of the international political economy of pharmaceuticals – that is, how the globalisation of the
pharmaceutical trade has regularly served as an international flashpoint, illuminating tensions
between states and markets.
As we signalled earlier in this article, civil society organisations such as Third World Network
(TWN) have been particularly active and we would refer readers to their website to access their pub-
lications: https://www.twn.my/. The work of TWN suggest the assumption that fake drugs constitute
an urgent and life threatening danger feeds into the past several decades’ attempts to regulate global
trade in pharmaceuticals. Similarly, wide-spread suspicions about the safety of the global pharma-
ceutical supply has been shown to serve the interests of some countries’ pharmaceutical sectors,
whilst undermining the interests of others.
Whilst these debates are significant, our task in this paper has been to investigate how fake drugs
have become a widely accepted concern in global public health research. Along the way, many col-
leagues asked if our research served to ‘expose big pharma’ – that is, to document collusion between
scholars and industry. Although other academics have demonstrated this meticulously (e.g. Sis-
mondo, 2018), this was neither our question not our aim. We neither looked for nor found a
nexus between scholars and pharmaceutical manufacturers. Even though this dynamic exists in
the world of scholarly publishing (as Sismondo convincingly demonstrates), it does not seem plaus-
ible that it could account for all of the publications we came across in which claims about the exist-
ence and effects of fake drugs in absence of robust evidence.
Instead, our epistemic audit of global public health scholarship on fake drugs suggests that this
scholarship is both shaped and sustained by cultures of knowledge production. As with all forms
of culture, these cultures of knowledge production have some assumptions at their core. The key
assumptions of this culture of scholarship is that the oft-repeated claims about the urgent dangers
presented by fake drugs is self-evident. We suggest that one significant effect of these assumptions
is that research does not focus on why fakes are difficult to measure, evidence and conceptualise
and for these assumptions to be worthy of interrogation. In particular, we note that global health
scholarship is not, in the main, asking questions about the conditions that foreclose access to
data. Nor are the papers published questioning their assumptions and about the self-evident nature
of ‘the problem of fake drugs’. We are concerned that not questioning these assumptions in the face
of what we refer to as ‘evidence gaps’ may in and of itself mitigate against the very possibility of rea-
lising any ‘truth’ of fake drugs. By bringing sociological, anthropological and historical method-
ologies to bear on understanding this culture of knowledge, we suggest that global health research
may have much to gain by fostering a more critical gaze towards the structural forces and material
conditions that shape what we know and how we come to know it.
Notes
1. The on-going research project, ‘What’s at stake in the fake? Indian pharmaceuticals, African markets and global
health’, charts the rise of worries about fake drugs – particularly worries about the safety of Indian pharma-
ceutical exports as they circulate in African markets – and assesses the impact that these worries have had across
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policy and research communities, as well as among consumers: ‘What’s at stake in the fake? Indian pharma-
ceuticals, African markets and global health’. Wellcome Trust Collaborative Award in the Humanities and
Social Sciences 212584/Z/18/Z. Investigators: Sarah Hodges, Julia Hornberger, Rene Gerrets.
2. A notable exception is Pisani et al. (2019). Their work, grounded in political economy (that is, the relationship
between states and markets), points to how it might be possible to target real-time in market quality sampling in
ways that look promising.
3. It is precisely this finding that forms the basis for the research questions at the heart of the on-going research
project, ‘What’s at stake in the fake? Indian pharmaceuticals, African markets and global health’ (2018–2023).
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